Author:
Søndergaard Marianne Baastrup,Madsen Frederik Roager,Sverrild Asger,Porsbjerg Celeste
Abstract
In the last 30 years, the treatment of obstructive lung diseases, such as asthma and COPD, has seen significant advancements. Introduction of inhaled corticosteroids (ICS) and, more recently, biological treatments has revolutionized care. Biological treatments are very successful in severe asthma and are expected to be approved for COPD soon. Systematic assessment and multidimensional treatment approaches are crucial in both conditions. Future care may involve specialized centres for severe obstructive lung diseases, focusing on personalized approaches and monitoring, as argued in this review.
Publisher
Danish Medical Association
Reference29 articles.
1. Soendergaard MB, Hansen S, Bjerrum AS et al. Complete response to anti-interleukin-5 biologics in a real-life setting: results from the nationwide Danish Severe Asthma Register. ERJ Open Res. 2022;8(4):00238-02022. doi: https://doi.org/10.1183/23120541.00238-2022
2. Regionernes Kliniske Kvalitetsudviklingsprogram. Dansk register for Kronisk Obstruktiv Lungesygdom - DrKOL. Årsrapport for 2022. Regionernes Kliniske Kvalitetsudviklingsprogram, 2023. www.sundhed.dk/content/cms/90/4690_drkol-aarsrapport-2022_offentlig.pdf (jan 2024).
3. Clark VL, Gibson PG, Genn G et al. Multidimensional assessment of severe asthma: a systematic review and meta-analysis. Respirology. 2017;22(7):1262-1275. doi: https://doi.org/10.1111/resp.13134
4. Porsbjerg C, Melén E, Lehtimäki L, Shaw D. Asthma. Lancet. 2023;401(10379):858-873. doi: https://doi.org/10.1016/S0140-6736(22)02125-0
5. Menzies-Gow A, Corren J, Bourdin A et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. doi: https://doi.org/10.1056/NEJMoa2034975